Daiichi Sankyo appoints executive VP
This article was originally published in Scrip
Daiichi Sankyo Pharma Development (DSPD) has appointed Dr Mahmoud Ghazzi executive vice-president of drug development for the Americas region. DSPD is responsible for the regional delivery of global clinical trials throughout the Americas, and Dr Ghazzi will oversee functions such as clinical development, regulatory affairs, and clinical safety & pharmacovigilance. He previously served at GlaxoSmithKline and Pfizer managing clinical trials for a variety of drugs.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.